The agreement gives VitroScreen a non-exclusive right to market and sell SenzaGen’s test platform GARD™ to customers looking to optimize their in vitro testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its precision and reliability, GARD™ improves the quality of customers’ decision-making and contributes to increased product safety in people’s everyday lives.
“VitroScreen is a perfect partner for us – they are in vitro specialists and aim at offering the latest testing methods, they address the industries we prioritize, and they drive the change to establish alternative testing methods. With the agreement, VitroScreen can offer GARD™ to customers who want to test both during their product development and to support their product registrations. We are now establishing the GARD™ technology in Italy and are strengthening our presence in the important European market”, says Axel Sjöblad, CEO of SenzaGen.
VitroScreen, Leading Innovation in Pre-clinical Testing, is a privately owned GLP-certified in vitro research laboratory established in 2001 by Dr Marisa Meloni. The laboratory offers alternative preclinical testing to customers in the pharmaceutical, medical device, cosmetics, chemical, agrochemicals and nutritional industries.
“VitroScreen always strives to offer its customers the most predictive, robust and reproducible in vitro approach to hazard identification. With SenzaGen’s GARD™, we provide our customers with a unique alternative platform with unparallel accuracy meeting the needs of several industries, notably for the assessment of potential respiratory sensitizers. We also look forward to working with a partner who shares our values and who contributes actively to a sustainable and ethical development of pre-clinical testing market”, says Marisa Meloni, CEO of VitroScreen.
The agreement between SenzaGen and VitroScreen runs for three years with an option to extend for additional years.
For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email: email@example.com | Mobil: +46 705-35 93 51
Tina Dackemark Lawesson, VP Marketing & Communications
Email: firstname.lastname@example.org | Mobil: +46 708-202944
GARD® consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on animals – which only achieves 70-75 percent accuracy. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.
About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct in Sweden and the US, and through partners in several other countries. Over the next few years the company will grow geographically, make alliances with additional distribution and license partners, and launch new unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 email@example.com, is the company’s Certified Adviser.